MODERNA cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow adoption of its respiratory syncytial virus (RSV) shot and weak demand for Covid-19 vaccines, sending its shares down more than 24 percent in early trading.
Demand for its Covid vaccine has been waning since the pandemic, while adoption of its RSV shot its second approved product has been slower than expected, forcing Moderna to cut costs.
